Amoxicillin + clavulanic acid
Taromentin is an antibiotic that works by killing bacteria that cause infections.
Taromentin contains two different medicines: amoxicillin and clavulanic acid. Amoxicillin belongs to a group of medicines called "penicillins", which are sometimes inactivated (made ineffective) by bacteria. The other active ingredient (clavulanic acid) stops this inactivation.
Taromentin is used in infants, children, and adults to treat the following infections:
➢ If any of the above applies to the patient, they should not take Taromentin.
If in doubt, the patient should consult their doctor or pharmacist before taking Taromentin.
Before taking Taromentin, the patient should consult their doctor, pharmacist, or nurse if they:
If in doubt whether any of the above applies to the patient, they should consult their doctor or pharmacist before taking Taromentin.
In some cases, the doctor may test the type of bacteria that caused the patient's infection.
Depending on the results, the patient may be given Taromentin in a different dose or a different medicine.
Taking Taromentin may worsen the course of certain diseases or cause severe side effects, including allergic reactions, seizures, and colitis. The patient should be aware of certain symptoms during Taromentin treatment to minimize the risk of any problems. See 'Conditions to be aware of' in section 4.
If the patient is to have blood tests (such as red blood cell tests or liver function tests) or urine tests (for glucose), they should inform their doctor or nurse that they are taking Taromentin. Taromentin may affect the results of these tests.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
If the patient is taking allopurinol (used for gout) at the same time as Taromentin, they may be more likely to experience skin allergic reactions.
If the patient is taking probenecid (used for gout), their doctor may decide to adjust the dose of Taromentin.
If the patient is taking blood-thinning medicines (such as warfarin) at the same time as Taromentin, they may need to have additional blood tests.
Taromentin may affect the action of methotrexate (a medicine used to treat cancer or rheumatic diseases).
Taromentin may affect the action of mycophenolate mofetil (a medicine used to prevent transplant rejection).
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should ask their doctor for advice before taking this medicine.
The medicine contains 1.7 mg of aspartame in each 1 mL and 8.5 mg of aspartame in each 5 mL of the prepared oral suspension.
Aspartame is a source of phenylalanine. It may be harmful to patients with phenylketonuria.
This is a rare genetic disorder in which phenylalanine accumulates in the body due to its improper elimination.
Considering the dosing schedule presented in section 3, the maximum amount of aspartame that can be administered to a patient in a single dose is 18.64 mg, and in a daily dose, 59.67 mg.
The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means the medicine is considered "sodium-free".
Considering the dosing schedule presented in section 3, the maximum amount of sodium that can be administered to a patient in a single dose is 5.99 mg, and in a daily dose, 19.19 mg.
The medicine contains 2.69 mg of sodium in 5 mL of the prepared oral suspension.
The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means the medicine is considered "sodium-free".
Considering the dosing schedule presented in section 3, the maximum amount of sodium that can be administered to a patient in a single dose is 5.99 mg, and in a maximum daily dose, 19.19 mg.
If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking the medicine.
The medicine contains 11.16 mg (0.29 mmol) of potassium per dose, which should be taken into account in patients with reduced kidney function and in patients controlling their potassium intake.
Considering the dosing schedule presented in section 3, the maximum amount of potassium that can be administered to a patient in a single dose is 24.46 mg (0.63 mmol), and in a daily dose, 78.32 mg (2.00 mmol). This should be taken into account in patients with reduced kidney function or controlling their potassium intake.
Taromentin should always be taken as directed by the doctor. If in doubt, the patient should consult their doctor or pharmacist.
All doses are determined based on the child's body weight in kilograms.
The doctor may perform more frequent blood tests to check how the patient's liver is functioning.
If the patient has taken more Taromentin than they should, they may experience symptoms such as stomach and intestinal irritation (nausea, vomiting, or diarrhea) or seizures. They should contact their doctor as soon as possible. They should take the carton and the remaining medicine with them to show the doctor.
If a dose of Taromentin is missed, it should be taken as soon as possible after remembering. The next dose should not be taken too early, but the patient should wait about 4 hours before taking the next dose.
The patient should continue taking Taromentin until the end of the treatment, even if they feel better. All doses of the medicine are necessary to combat the infection. If some bacteria survive, they may cause a relapse of the infection.
If in doubt about taking the medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Taromentin can cause side effects, although not everybody gets them.
The following are side effects of Taromentin that may occur.
➢
Colitis, causing watery diarrhea, usually with blood and mucus, abdominal pain, and (or) fever.
If the patient has severe and persistent stomach pain, it may be a sign of acute pancreatitis.
Drug-induced enterocolitis syndrome occurred mainly in children taking amoxicillin with clavulanic acid. It is a type of allergic reaction, with recurring vomiting (1 to 4 hours after taking the medicine) as the leading symptom. Further symptoms may include abdominal pain, lethargy, diarrhea, and low blood pressure.
➢
Very common side effects(may affect more than 1 in 10 people)
Common side effects(may affect up to 1 in 10 people)
Uncommon side effects(may affect up to 1 in 100 people)
Rare side effects(may affect up to 1 in 1,000 people)
Other side effects have occurred in a very small number of patients, but their exact frequency is not known.
form causing widespread skin peeling (more than 30% of the body surface - toxic epidermal necrolysis)
Side effects that may appear in blood or urine test results:
If side effects occur, including any not listed in this leaflet, the patient should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
Keep out of the sight and reach of children.
Dry powder - store in a temperature below 25°C. Protect from moisture.
Oral suspension - store in the refrigerator at 2°C to 8°C for up to 7 days.
Do not take the medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer need. This will help protect the environment.
White to light yellow powder, which forms a uniform suspension after the addition of water.
Packaging:1 bottle in a cardboard box containing 6.3 g, 12.6 g, or 25.2 g of powder.
After the addition of water, the bottle contains 35 mL, 70 mL, or 140 mL of suspension, respectively.
A measuring spoon is provided with each pack of the medicine, allowing the administration of 1.25 mL, 2.5 mL, and 5 mL of the suspension. An oral syringe is also provided with each pack of the medicine, allowing the administration of up to 5 mL of the suspension with an accuracy of 0.1 mL.
Taromentin is also available in the form of powder for solution for injection or infusion and in the form of oral tablets.
Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna, ul. A. Fleminga 2, 03-176 Warsaw, Phone: 22 811-18-14. For more information about this medicine, the patient should contact the marketing authorization holder.
Antibiotics are used to treat bacterial infections. They are ineffective in treating viral infections.
Sometimes, bacterial infections do not respond to antibiotic treatment.
One of the most common reasons for this phenomenon is that the bacteria are resistant to the administered antibiotic.
This means that the bacteria can survive or multiply despite the use of the antibiotic.
Bacteria can become resistant to antibiotics for many reasons. Careful use of antibiotics can help reduce the possibility of bacteria becoming resistant.
The antibiotic prescribed by the doctor is intended solely for the treatment of the current illness. Paying attention to the following tips will help prevent the development of resistant bacteria, which could render the antibiotic ineffective.
---------------------------------------------------------------------------------------------------------------------------
Before adding the recommended amount of water, the patient should shake the bottle with the medicine to loosen the powder.
Add boiled, cooled water to the bottle containing 6.3 g of powder, up to the mark on the label (31 mL). Shake until a uniform suspension is obtained. After standing, if necessary, fill with water to the mark. This will give 35 mL of suspension.
Add boiled, cooled water to the bottle containing 12.6 g of powder, up to the mark on the label (62 mL). Shake until a uniform suspension is obtained. After standing, if necessary, fill with water to the mark. This will give 70 mL of suspension.
Add boiled, cooled water to the bottle containing 25.2 g of powder, up to the mark on the label (124 mL). Shake until a uniform suspension is obtained. After standing, if necessary, fill with water to the mark. This will give 140 mL of suspension.
The suspension should be shaken vigorously before each use.
5 mL of the suspension contains 400 mg of amoxicillin and 57 mg of clavulanic acid.
2.5 mL of the suspension contains 200 mg of amoxicillin and 28.5 mg of clavulanic acid.
1.25 mL of the suspension contains 100 mg of amoxicillin and 14.25 mg of clavulanic acid.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.